Lamisil and Dermatitis exfoliative - a phase IV clinical study of FDA data

Summary:

Dermatitis exfoliative is reported as a side effect among people who take Lamisil (terbinafine hydrochloride), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Diprosone, and have Nail tinea.

The phase IV clinical study analyzes which people have Dermatitis exfoliative when taking Lamisil. It is created by eHealthMe based on reports of 13,455 people who have side effects when taking Lamisil from the FDA, and is updated regularly.

What is Lamisil?

Lamisil has active ingredients of terbinafine hydrochloride. It is often used in pulmonary aspergilloma (mycetoma). eHealthMe is studying from 14,080 Lamisil users. Check the latest studies of Lamisil.

What is Dermatitis exfoliative?

Dermatitis exfoliative (widespread scaling of the skin, often with itching (pruritus), skin redness (erythroderma), and hair loss) is found to be associated with 688 drugs and 945 conditions by eHealthMe. Check the latest studies of Dermatitis exfoliative.

On Jul, 08, 2026

13,455 people reported to have side effects when taking Lamisil.
Among them, 144 people (1.07%) have Dermatitis exfoliative.

Could Lamisil cause Dermatitis exfoliative?

Among these 144 people:

How long have people been on Lamisil when they have Dermatitis exfoliative? *

Click here to view more results

What is the gender of people who have Dermatitis exfoliative when taking Lamisil? *

Click here to view

What is the age of people who have Dermatitis exfoliative when taking Lamisil? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Lamisil and have Dermatitis exfoliative?

- Check whether Dermatitis exfoliative is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lamisil:

Lamisil (14,080 reports)

Dermatitis exfoliative treatments and more:

Dermatitis exfoliative (6,561 reports)

How severe was Dermatitis exfoliative and when was it recovered:

Dermatitis exfoliative in Lamisil

Expand to all the drugs that have ingredients of terbinafine hydrochloride:

Dermatitis exfoliative and drugs with ingredients of terbinafine hydrochloride

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lamisil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dermatitis exfoliative:

Dermatitis exfoliative (688 drugs)

Browse all the conditions that are associated with Dermatitis exfoliative:

Dermatitis exfoliative (945 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on terbinafine hydrochloride (the active ingredients of Lamisil) and Lamisil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.